Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Position Reduced by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich trimmed its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 91.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,084 shares of the biotechnology company’s stock after selling 23,201 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Arcturus Therapeutics were worth $39,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Arcturus Therapeutics by 10.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 846 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Arcturus Therapeutics by 3.7% in the fourth quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock worth $1,097,000 after purchasing an additional 2,335 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Arcturus Therapeutics by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock worth $4,587,000 after purchasing an additional 3,224 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 3,705 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Arcturus Therapeutics by 1.1% in the third quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock worth $12,810,000 after purchasing an additional 5,789 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Stock Down 7.6 %

Shares of ARCT stock opened at $13.21 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 12 month low of $12.75 and a 12 month high of $45.00. The business’s 50 day moving average is $16.83 and its two-hundred day moving average is $18.44. The company has a market cap of $357.82 million, a PE ratio of -5.95 and a beta of 2.96.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. As a group, equities analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ARCT has been the subject of a number of research analyst reports. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a “buy” rating in a report on Monday. HC Wainwright dropped their price objective on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, Wells Fargo & Company dropped their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $59.20.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.